Lumbar myelography with iohexol and metrizamide. A comparative multicenter prospective study.
Diagnostic quality and adverse reactions associated with metrizamide and iohexol as contrast agents for lumbar myelography were compared in a prospective randomized double-blind study in 350 patients at seven centers. Both contrast media were administered in comparable volumes at a concentration of 180 mg I/ml. Overall quality of radiographic visualization was graded as "good" or "excellent" in 95% of 175 metrizamide studies and in 98% of 175 iohexol myelograms. Ninety-three patients examined with metrizamide (53%) and 130 patients studied with iohexol (74%) experienced no discomfort during or after myelography. The incidence of postmyelographic headache was 38% with metrizamide and 21% with iohexol. Nausea and vomiting were also more common with metrizamide. Five patients examined with metrizamide (3%) experienced transient confusion and disorientation after lumbar myelography. No such reactions were observed after iohexol myelography.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D003221:Confusion / Q000139:chemically induced; D003287:Contrast Media / Q000009:adverse effects; D004311:Double-Blind Method; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007463:Iodobenzoates; D007472:Iohexol; D008297:Male; D008793:Metrizamide / Q000009:adverse effects; D008875:Middle Aged; D009192:Myelography; D009325:Nausea / Q000139:chemically induced; D011446:Prospective Studies; D011897:Random Allocation; D014283:Triiodobenzoic Acids / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007472:Iohexol; D008793:Metrizamide